EXT 705
Alternative Names: EXT-705Latest Information Update: 28 Aug 2020
At a glance
- Originator Extend Biosciences
- Class Antihyperglycaemics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Diabetes-mellitus in USA (SC, Injection)
- 17 Apr 2020 EXT 705 is available for licensing as of 17 Apr 2020. https://extendbio.com/partnering/